Impact Factor
3.39
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.58
692 total citations
h5-index
28
h5 depth signal
Cited share
76.3%
209 of 274
Total citations
692
Citation footprint
Metric signal
2.40
External metric anchor
Self-citation
2.6%
18 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,256
China
66
Canada
65
Japan
24
Australia
23
Citing Fields of Research
Cardiology
298
Hematology
201
Antibiotic & Antibacterial Agents
189
Respiratory Support
185
Anesthetic & Pain Medicine
159
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
10,741
Articles tracked across the journal lifetime
Indexed publication set
274
209 cited publications
Last 12 months
188
15.7 publications/month
Open access share
7.4%
14 OA publications in the last year
Leading citing country
United States
1,256 citing publications
Leading citing field
Cardiology
298 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v26n1, 1992-
v26n1, 1992-
1992-1994
1995-1999
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Antibiotic & Antibacterial Agents
Anesthetic & Pain Medicine
Hematology
Respiratory Support
Diabetes
Broad Categories
Drug Therapy
Pharmacology
Diabetes
Cardiology
Antibiotic & Antibacterial Agents
Respiratory Support
Hematology
Urology
MeSH Descriptors
Drug Therapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/10600280261474866
Open DOI
Efficacy and Safety of Tradipitant for Motion Sickness—A GRADE Assessed Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of tradipitant, a neurokinin-1 (NK1) receptor antagonist, for preventing motion sickness–induced vomiting. Data Sources: PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov were searched ...
02
DOI 10.1177/10600280261493982
Open DOI
The Potential Impact of Selective Serotonin Reuptake Inhibitors on Delayed Onset Muscle Soreness: A Prospective Cohort Study
Background: Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for mood disorders. Their association with musculoskeletal side effects raises the question of potential SSRI impact on exercise-induced muscle damage and ...
03
DOI 10.1177/10600280261494015
Open DOI
Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol
Objective: This article describes pharmacology, pharmacokinetics, safety, and efficacy data of enlicitide, the first Food and Drug Administration (FDA)-approved oral proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i). Data ...
04
DOI 10.1177/10600280261492707
Open DOI
Manufacturing Quality Issues in Healthcare and Cosmetics: An Analysis of FDA Surveillance Data
Background: Poor manufacturing quality in healthcare and cosmetic products expose people to danger and needs further categorization and assessment. Objective: This study reviewed Food and Drug Administration (FDA) records to identify maj...
05
DOI 10.1177/10600280261491998
Open DOI
Low-Dose Buprenorphine Initiation Strategies for Pain
Objective: The purpose of this review is to describe the common benefits and pitfalls of various low-dose buprenorphine initiation strategies for patients experiencing long-term pain without opioid use disorder (OUD). Data sources: A sea...
06
DOI 10.1177/10600280261493131
Open DOI
Ritlecitinib in Nonsegmental Vitiligo: A Systematic Review and Comprehensive Program Synthesis of Clinical Efficacy, Safety, and Biomarker Outcomes
Objective: To evaluate the clinical efficacy and safety of oral ritlecitinib, a selective Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor, for the treatment of nonsegmental vi...
07
DOI 10.1177/10600280261495089
Open DOI
Objective Limitations of Qualitative TOF Monitoring in ARDS
08
09
DOI 10.1177/10600280261491400
Open DOI
Retrospective Evaluation of the Association of Hypoalbuminemia With Acute Treatment Outcomes in Methicillin-Susceptible Staphylococcus Aureus Bacteremia
Background: Cefazolin and antistaphylococcal penicillins (ASP) are first-line agents for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. These agents are substantially protein-bound; however, scant data exist evaluating ...
10
DOI 10.1177/10600280261487728
Open DOI
Real-World Postdischarge P2Y12 Inhibitor Use After Ischemic Stroke and Transient Ischemic Attack, 2020 to 2024
Background: P2Y12 inhibitor acquisition and continuation after ischemic stroke or transient ischemic attack (TIA) are incompletely characterized. Objective: To describe postdischarge clopidogrel and ticagrelor uptake, persistence, switch...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 29, no. 3 (MAR 1995)19950517 Notice not published Printed on acid-free paper